Related references
Note: Only part of the references are listed.Newborn screening for lysosomal storage diseases: an ethical and policy analysis
Lainie Friedman Ross
JOURNAL OF INHERITED METABOLIC DISEASE (2012)
Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria
Thomas P. Mechtler et al.
LANCET (2012)
Fabry disease: Biochemical, pathological and structural studies of the α-galactosidase A with E66Q amino acid substitution
Tadayasu Togawa et al.
MOLECULAR GENETICS AND METABOLISM (2012)
Consensus treatment recommendations for late-onset Pompe disease
Edward J. Cupler et al.
MUSCLE & NERVE (2012)
Newborn Screening for Lysosomal Storage Disorders
Kimitoshi Nakamura et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART C-SEMINARS IN MEDICAL GENETICS (2011)
Update on role of agalsidase alfa in management of Fabry disease
Uma Ramaswami
DRUG DESIGN DEVELOPMENT AND THERAPY (2011)
Cerebral hemorrhage in Fabry's disease
Katsuya Nakamura et al.
JOURNAL OF HUMAN GENETICS (2010)
Mutations of the GLA gene in Korean patients with Fabry disease and frequency of the E66Q allele as a functional variant in Korean newborns
Beom Hee Lee et al.
JOURNAL OF HUMAN GENETICS (2010)
Four-Year Prospective Clinical Trial of Agalsidase Alfa in Children with Fabry Disease
Raphael Schiffmann et al.
JOURNAL OF PEDIATRICS (2010)
Fabry disease: a review of current management strategies
A. Mehta et al.
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE (2010)
Newborn Screening for Fabry Disease in Taiwan Reveals a High Incidence of the Later-Onset GLA Mutation c.936+919G > A (IVS4+919G > A)
Wuh-Liang Hwu et al.
HUMAN MUTATION (2009)
Recommendations on Diagnosis, Treatment, and Monitoring for Gaucher Disease
Ana Maria Martins et al.
JOURNAL OF PEDIATRICS (2009)
The g.1170C>T polymorphism of the 5′ untranslated region of the human alpha-galactosidase gene is associated with decreased enzyme expression-Evidence from a family study
J. P. Oliveira et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2008)
Effect of single-nucleotide polymorphisms of the 5′ untranslated region of the human α-galactosidase gene on enzyme activity, and their frequencies in Portuguese caucasians
J. P. Oliveira et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2008)
Enzyme replacement in Fabry disease: Pharmacokinetics and pharmacodynamics of agalsidase alfa in children and adolescents
Markus Ries et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Fabry disease: Baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry
C. M. Eng et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2007)
Agalsidase-beta therapy for advanced Fabry disease - A randomized trial
Maryam Banikazemi et al.
ANNALS OF INTERNAL MEDICINE (2007)
Enzyme replacement therapy with agalsidase alfa in children with Fabry disease
U. Ramaswami et al.
ACTA PAEDIATRICA (2007)
Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease
Markus Ries et al.
PEDIATRICS (2006)
High incidence of later-onset Fabry disease revealed by newborn screening
Marco Spada et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2006)
Clinical manifestations of Fabry disease in children: Data from the Fabry outcome survey
U Ramaswami et al.
ACTA PAEDIATRICA (2006)
Fabry disease: correlation between structural changes in a-galactosidase, and clinical and biochemical phenotypes
F Matsuzawa et al.
HUMAN GENETICS (2005)
Long-term safety and efficacy of enzyme replacement therapy for Fabry disease
WR Wilcox et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2004)
Fabry disease: overall effects of agalsidase alfa treatment
M Beck et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2004)
Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease - A prospective strain rate imaging study
F Weidemann et al.
CIRCULATION (2003)
Fabry disease:: 45 novel mutations in the α-galactosidase A gene causing the classical phenotype
J Shabbeer et al.
MOLECULAR GENETICS AND METABOLISM (2002)
Alternative splicing in the α-galactosidase A gene:: Increased exon inclusion results in the Fabry cardiac phenotype
S Ishii et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2002)
Safety and efficacy of recombinant human α-galactosidase a replacement therapy in Fabry's disease.
CM Eng et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Enzyme replacement therapy in Fabry disease - A randomized controlled trial
R Schiffmann et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Fabry disease: enzymatic diagnosis in dried blood spots on filter paper
NA Chamoles et al.
CLINICA CHIMICA ACTA (2001)
Share Paper
